Clinical Trial

The Treatment of PD-1 Antibody Combined With Peg-IFNα in NAs-suppressed CHB Patients

Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
This is a prospective, open-labled, randomized controlled study to assess efficacy and safety of treatment with Sintilimab (PD-1 antibody) combined Peg-IFNα-2b in CHB patients on stable NAs treatment.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-04-09; most recent amendment 2026-03-16.
Status change: Recruiting → Active, Not Recruiting 2026-03-16
Status change: Not Yet Recruiting → Recruiting 2024-05-07
Trial Details
NCT Number NCT06357806
Lead Sponsor Beijing 302 Hospital
Conditions Chronic Hepatitis B
Enrollment 45 participants
Start Date 2024-05-17
Primary Completion 2026-10-08 (estimated)
Study Completion 2026-10-08 (estimated)
Updated on ClinicalTrials.gov 2026-03-18